The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...

Alabama has moved up the most recent obesity rankings from U.S. News & World Report. And we’re getting awfully close to the ...

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

According to a new scientific study published in the journal Nature Metabolism, non-caloric sweeteners (often found in diet ...

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...

Men with gout and obesity receiving febuxostat-based ULT were less likely to achieve SU targets and more frequently experienced disease flares.

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

The strategy of rewiring the brain's stress response is rooted in two pieces of scientific literature. One is biochemical.

Weight-loss drugs and bariatric surgery both have an impact on cancer risk. A new study breaks down the link and how GLP-1 ...

Israel is grappling with a growing obesity epidemic, with nearly one in five children aged 6-9 suffering from obesity and ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.